Topical Menthol for CIPN: a Randomized, Placebo Controlled Phase II Trial
To assess whether six week treatment with BID topical Menthol application will decrease
persistent neuropathic pain as measured by the change in Brief Pain Inventory-Short Form
(BPI-SF worst pain score), following neoadjuvant/adjuvant chemotherapy with taxanes or
oxaliplatin-based regimens among breast and colorectal cancer patients.
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care
measured by BPI
United States: Institutional Review Board